Quantumbio Inc

Addressing Structural Disorder and Conformational Heterogeneity in Modern Therapeutic Modalities: a Unified X-ray/cryo-em QM/MM Ensemble Refinement Toolkit With Enhanced Density-driven MD - Abstract Accurate Determination of Protein–ligand Interactions Fundamentally Shapes Drug Discovery, Directly Influencing Lead Optimization and Therapeutic Development. Despite Advances in X-ray Crystallography and Cryogenic Electron Microscopy (cryo-em), Traditional Refinement Methods Still Struggle Significantly With Intrinsic Disorder, Flexibility, and Conformational Heterogeneity. Approximately 69% of Protein Data Bank (PDB) Structures Contain Missing or Unresolved Residues, Especially at Resolutions Worse Than 2.75 Å. This Pervasive Issue Severely Limits Structural Accuracy, Particularly for Complex, Therapeutically Critical Modalities Like Macrocycles, Protacs, Cyclic Peptides, Covalent Inhibitors, and Metal-containing Ligands. Moreover, the Accuracy of Ai-driven Structure Prediction Models (e.g., Alphafold, Openfold) Strongly Depends Upon High-quality Experimental Data, Highlighting the Urgent Need for Improved, Ensemble-based Structural Refinement. Conventional Refinement Protocols Predominantly Rely on Single-conformer Assumptions and Simplified Stereochemical Restraints, Frequently Missing Critical Alternative Binding Modes and Ligand-induced Structural Changes. Simulated Annealing (SA) Methods Help Avoid Local Minima But Typically Converge on Single Optimized Structures, Inadequately Capturing True Biological Flexibility. Conversely, Ensemble Refinement (ER) Explicitly Models Structural Heterogeneity Through Simultaneous Multi-conformer Refinement, Capturing Relevant Functional States. However, Existing Er Implementations Generally Employ Simplistic Force Fields and Basic Molecular Dynamics (MD), Limiting Their Accuracy, Efficiency, and Pharmaceutical Utility. to Overcome These Limitations, We Propose a Novel, Unified X-ray/cryo-em Pipeline Integrating Our Robust, Linear-scaling Quantum Mechanics/molecular Mechanics (QM/MM) Engine (divcon), Advanced Density-driven Conformational Sampling (including Omitted Loop and Sidechain Completion and Protonation State Determination), Automated Protomer/tautomer Enumeration, and Real-space Z-score Density Difference (ZDD) Scoring (xmodescore). Crucially, This New Platform Will Incorporate an Integrated Gpu-accelerated Molecular Dynamics Engine Supporting Enhanced MD Sampling (e.g., Replica Exchange, Metadynamics, Accelerated MD), Occupancy/b-factor Refinement, and Rigorous Clustering to Efficiently Capture Biologically Relevant Conformational Dynamics. Commercially, Our Approach Directly Addresses Longstanding Pharmaceutical Pain Points Related to Structural Ambiguity and Disorder, Providing Chemically Realistic, Actionable Structural Ensembles Suitable for Improved Drug Design. by Automating Ligand and Protein Preparation, Rigorously Modeling Challenging Drug Modalities, and Capturing Genuine Conformational Flexibility, Our Pipeline Surpasses Current Platforms in Structural Fidelity, Predictive Accuracy, and Practical Applicability to Modern Therapeutic Discovery.